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In atherosclerosis, the accumulation of apolipoprotein B-lipoproteins in the matrix beneath the
endothelial cell layer of blood vessels leads to the recruitment of monocytes, the cells of the
immune system that give rise tomacrophages and dendritic cells. Macrophages derived from these
recruited monocytes participate in a maladaptive, nonresolving inflammatory response that
expands the subendothelial layer due to the accumulation of cells, lipid, and matrix. Some lesions
subsequently form a necrotic core, triggering acute thrombotic vascular disease, includingmyocar-
dial infarction, stroke, and sudden cardiac death. This Review discusses the central roles of macro-
phages in each of these stages of disease pathogenesis.Atherosclerosis underlies the leading cause of death in industri-
alized societies and is likely soon to attain this status worldwide
(Lloyd-Jones et al., 2010). Atherosclerosis first involves
a decades-long expansion of the arterial intima, a normally small
area between the endothelium and the underlying smooth
muscle cells of the media, with lipids, cells, and extracellular
matrix (Figure 1). Although this process itself rarely leads tomajor
symptoms due to preservation of the arterial lumen, a few of
these lesions undergo necrotic breakdown, which precipitates
acute, occlusive lumenal thrombosis and its consequences:
myocardial infarction (‘‘heart attack’’), unstable angina (acceler-
ating chest pain due to ongoing heart muscle ischemia), sudden
cardiac death, and stroke (Virmani et al., 2002). This Review
discusses the impact of monocyte-derived macrophages in
both early atherogenesis and advanced plaque progression.
Lesion Initiation and Early Progression
Atherosclerosis is a focal disease process that occurs predom-
inantly at sites of disturbed laminar flow, notably, arterial branch
points and bifurcations. Careful morphological and functional
studies of the earliest stages of atherogenesis in human and
animal models indicate that the key initiating step is subendothe-
lial accumulation of apolipoprotein B-containing lipoproteins
(apoB-LPs; Figure 2) (Williams and Tabas, 1995). ApoB-LPs
are made by liver and intestinal cells and consist of a core of
neutral lipids, notably cholesteryl fatty acyl esters and triglycer-
ides, surrounded by a monolayer of phospholipid and proteins.
Hepatic apoB-LPs are secreted as very low-density lipoproteins
(VLDL), which are converted in the circulation to atherogenic
low-density lipoprotein (LDL), and intestinal apoB-LPs are
secreted as chylomicrons, which are converted by lipolysis
into atherogenic particles called remnant lipoproteins.
Monocyte Entry
The key early inflammatory response to retained apoB-LPs,
which may be enhanced by oxidative modification of the LPs,is activation of overlying endothelial cells in a manner that leads
to recruitment of blood-borne monocytes (Glass and Witztum,
2001; Mestas and Ley, 2008). Activated endothelial cells secrete
chemoattractants, or ‘‘chemokines,’’ that interact with cognate
chemokine receptors on monocytes and promote directional
migration (Figure 2 and Movie S1 available online). Importantly,
prevention of monocyte entry by blocking chemokines or their
receptors prevents or retards atherogenesis in mouse models
of atherosclerosis (Mestas and Ley, 2008). It should be noted
that, although early apoB-LP retention precedes and triggers
endothelial activation and monocyte entry, monocyte-derived
macrophages in the lesion may subsequently secrete apoB-
LP-binding proteoglycans (Williams and Tabas, 1995). This
mechanism likely plays an important role in the amplification of
LP retention once lesions become established, which in turn
can help to explain why the inflammation in atherosclerotic
lesions fails to resolve (Tabas, 2010a).
Monocytes originate from bone marrow-derived progenitor
cells, and this early stage ofmonocyte developmentmaybe regu-
lated by cellular cholesterol content in a manner that can affect
atherogenesis. Mice whose monocyte progenitor cells have
defective cholesterol efflux due to deficiency of ABCA1 and
ABCG1 transporters show an increase in circulating monocyte
number (monocytosis) and increased atherosclerosis (Yvan-
Charvet et al., 2010a). Importantly, both the monocytosis and
increased atherosclerosis are reversible by restoring cholesterol
efflux frommonocytes tohigh-density lipoprotein (HDL), and there
are correlations in humans among high HDL, lower blood mono-
cyte counts, and decreased risk for atherosclerosis (Coller, 2005).
The role of monocyte subsets in atherogenesis has been
a topic of great interest throughout the last decade. In mice,
hypercholesterolemia is associated with an increase in an
inflammatory monocyte subset referred to as Lychi, and these
cells enter developing atherosclerotic lesions more readily than
Lyclo monocytes. Data from other models of inflammation haveCell 145, April 29, 2011 ª2011 Elsevier Inc. 341
Figure 1. Progression of an Atherosclerotic Lesion
Early fatty streak lesions are characterized by the accumulation of apolipoprotein B-containing lipoproteins (apoB-LPs) in the subendothelial space, which incites
the recruitment of dendritic cells and macrophages. As the atherosclerotic lesion progresses, smooth muscle and T cells also infiltrate the intima, and apoB-LP
retention is amplified. Vulnerable plaques are characterized by the accumulation of apoptotic cells and defective phagocytic clearance (efferocytosis), resulting in
the lipid-filled necrotic core. A thinning fibrous cap decreases lesion stability, making these atherosclerotic plaques susceptible to rupture and the formation of
a thrombus.suggested that Lychi monocytes participate in the acute
response to inflammation, whereas Lyclo monocytes are associ-
ated with inflammation resolution (Arnold et al., 2007). However,
this scenario may not be directly applicable to atherosclerosis
because of the chronic nature of the inflammatory process,
and maximal suppression of atherogenesis requires genetic
manipulations that block entry of both subsets (Tacke et al.,
2007). Moreover, there are important differences in the charac-
terization and roles of monocyte subsets in humans versus
mice. Thus, the key issue as to whether monocyte subsets—
and the macrophages and other cells (e.g., dendritic cells)
derived from them—have different roles in atherogenesis or pla-
que progression remains unresolved.
Following chemokinesis, monocytes become tethered and roll
on endothelial cells overlying retained apoB-LPs, notably
through the interaction of monocyte P-selectin glycoprotein
ligand-1 (PSGL-1) with endothelial selectins (Mestas and Ley,
2008). Monocytes then become firmly adhered to lesional
endothelial cells through the interaction of monocyte integrins
with endothelial cell ligands, and recent evidence has implicated
monocyte type I interferon signaling in this process (Goossens
et al., 2010). Immunohistochemical analysis of human lesions
and molecular-genetic causation studies in gene-targeted
mice suggest that the monocyte integrins VLA-4 (very late
antigen-4) and LFA-1 (lymphocyte function-associated antigen
1) and their respective endothelial cell ligands, VCAM-1 (vascular
cell adhesion molecule) and ICAM-1 (intercellular adhesion
molecule-1), may be particularly important in the setting of early
atherogenesis. Moreover, it should be noted that platelet aggre-
gation on endothelium overlying atherosclerotic lesionsmay also
promote monocyte-endothelial interactions by activating NF-kB342 Cell 145, April 29, 2011 ª2011 Elsevier Inc.signaling and expression of adhesion molecules and by depos-
iting platelet-derived chemokines on activated endothelium
(Mestas and Ley, 2008; Koenen et al., 2009). Finally, firm
adhesion of monocytes is followed by their entry into the suben-
dothelial space (diapedesis) (Kamei and Carman, 2010).
Although diapedesis has been studied extensively in other
models of inflammation, work in atherogenesis is limited. In
particular, molecules that have been implicated in diapedesis
in vitro, such as tissue factor and PECAM-1, have not been
shown to participate in diapedesis in the setting of atherogenesis
per se (Goel et al., 2008; Harry et al., 2008). Part of this
complexity may be due to the multiple functions of these mole-
cules and the difficulty of assaying diapedesis in vivo.
Monocyte Differentiation into Macrophages
Driven by macrophage colony-stimulating factor (M-CSF) and
probably other differentiation factors, the majority of monocytes
in early atherosclerotic lesions become cells with macrophage-
and/or dendritic cell-like features (Johnson and Newby, 2009;
Paulson et al., 2010). There has been great interest in macro-
phage heterogeneity in atherosclerotic lesions, particularly
regarding macrophages involved in proinflammatory processes
(M1) versus those involved in resolution and repair (M2), but
a clear picture has not yet emerged from these studies (Johnson
and Newby, 2009). Much of the theory in this area has been
driven by in vitro studies exploring gene/protein expression
patterns and functional attributes of monocytes or macrophages
subjected to various treatments, including growth/differentiation
factors; cytokines derived from type 1 versus type 2 helper
T cells; transcription factors, notably PPARs; and even athero-
genic lipoproteins and lipids (Johnson and Newby, 2009;
Kadl et al., 2010). However, the situation in the atherosclerotic
Figure 2. ApoB-LP Retention Promotes Monocyte Recruitment and Subsequent Foam Cell Formation
Apolipoprotein B-containing lipoproteins (apoB-LPs) enter the intima, bind to proteoglycans, and undergo various modifications, including oxidation and
hydrolysis by secretory phospholipase A2 (sPLA2) and secretory sphingomyelinase (S-SMase). These modifications incite an inflammatory response charac-
terized by chemokine secretion and altered expression of adhesion molecules by the overlying endothelial cells. The modifications also contribute to lipoprotein
aggregation and further promote lipoprotein retention. The inflammatory signals lead to monocyte recruitment into the intima, where they differentiate into
macrophages and internalize native and modified lipoproteins, resulting in foam cell formation. Moreover, foam cells can contribute further to, and thus amplify,
lipoprotein modifications and retention (dotted arrow).subendothelium is almost certainly more complex, and there is
a significant gap between the in vitro and in vivo observations.
Future studies will need to focus on macrophage heterogeneity
characterized by differential expression of specific molecules
or molecular networks that have functional significance for
atherogenesis rather than heterogeneity based simply on the
aforementioned M1 versus M2 paradigm (Kadl et al., 2010).
Moreover, as discussed below, any discussion of ‘‘macrophage
heterogeneity’’ must take into account the role of dendritic-like
cells and the plasticity of myeloid-derived cells.
Foam Cells
Even at very early stages of atherogenesis, many macrophages
and dendritic-like cells have membrane-bound lipid droplets in
the cytoplasm. These lipid-loaded cells are called ‘‘foam cells,’’
and their formation begins when phagocytes ingest and process
apoB-LPs (Figure 2 and Movie S1). The mechanism of this
uptake is a widely studied and hotly debated area. Early work
suggested that uptake of oxidized LDL occurs via scavenger
receptors, notably the type A scavenger receptor (SRA) and
a member of the type B family, CD36 (Kunjathoor et al., 2002).
However, recent gene-targeting studies in apolipoprotein E
(ApoE-deficient mice), a widely used model of atherosclerosis
in which plasma lipoproteins are elevated due to absence of
the lipoprotein-clearing protein ApoE, indicate that additional
mechanisms of foam cell formation are also operational in
atherosclerosis (Moore et al., 2005; Manning-Tobin et al.,2009). In vitro work offers plausible mechanisms, including
phagocytosis of matrix-retained and aggregated LPs and fluid
phase pinocytosis of nonretained native LDL (Tabas et al.,
1993; Kruth et al., 2005). Further mechanistic and in vivo studies
are needed to fully assess the relative importance of these
processes, taking into account stage and location of lesions
and the particular model being investigated.
Once ingested, the cholesteryl esters of the LPs are hydro-
lyzed in late endosomes to cholesterol, often referred to as
free cholesterol, and fatty acids (Maxfield and Tabas, 2005).
Late endosomal free cholesterol is trafficked to peripheral
cellular sites by poorly understood mechanisms involving the
late endosomal proteins NPC1 and NPC2 and the lipid lysobi-
sphosphatidic acid. Recent work also points to a possible role
of the ABC transporter protein ABCG1 in this process (Tarr and
Edwards, 2008). Delivery of free cholesterol to the endoplasmic
reticulum (ER) has important roles in downregulating both LDL
receptors and endogenous cholesterol synthesis by suppressing
the sterol-regulatory element binding pathway (SREBP) (Brown
and Goldstein, 1997). Moreover, the free cholesterol undergoes
re-esterification to cholesteryl fatty acid esters (the ‘‘foam’’ of
foam cells) by the ER enzyme acyl-CoA:cholesterol ester trans-
ferase (ACAT) (Brown et al., 1980). Defects in ACAT function or
processes involved in cholesterol efflux from cells lead to free
cholesterol-induced cytotoxicity and may promote macrophage
death in advanced lesions, or ‘‘atheromata’’ (discussed below).Cell 145, April 29, 2011 ª2011 Elsevier Inc. 343
Free cholesterol released from lysosomes and from rehydro-
lyzed cholesteryl ester droplets can also traffic to the plasma
membrane and thus be available for efflux out of the cell (Tall
et al., 2008; Rothblat and Phillips, 2010). Cholesterol efflux is
thought to be a major process involved in plaque regression
when hypercholesterolemia is reversed. This expansive area
has been covered in many reviews over the last decade, and
here we will briefly summarize several key points. The mecha-
nisms and exact route of cholesterol transport to the plasma
membrane are not fully known, although Golgi-to-plasma
membrane vesicular transport may be involved (Chang et al.,
2006; Maxfield and Tabas, 2005). Interestingly, trafficking of
free cholesterol out of lysosomes may become defective in
lesional macrophages, which would constitute a barrier to
cholesterol efflux and lesion regression (Jerome, 2006). Once
at the plasma membrane, cholesterol is transferred to the outer
leaflet, where it is removed from the cells by ABCA1- and
ABCG1-mediated transport to apolipoprotein A1 and HDL,
respectively, or by ‘‘passive diffusion’’ to cholesterol-poor HDL
(Tall et al., 2008; Rothblat and Phillips, 2010). As predicted, dele-
tion of both ABCA1 and ABCG1 in macrophages enhances
atherosclerosis in mice (Tall et al., 2008). Interestingly, deletion
of ABCG1 alone in macrophages suppresses atherogenesis,
which has been ascribed to either compensatory induction of
ABCA1 and ApoE or to ‘‘beneficial’’ depletion of early lesional
macrophages by oxysterol-induced apoptosis (Ranalletta
et al., 2006; Tarling et al., 2010).
Extensive in vitro and in vivo work has focused on how sterol-
regulated transcription factors, LXRa and LXRb (LXR), induces
ABCA1 and ABCG1 and, through this and other mechanisms,
promote regression of foam cell lesions (Calkin and Tontonoz,
2010). Evidence that ABC transporters, LXR, and other mole-
cules carry out cholesterol efflux and ‘‘reverse cholesterol trans-
port’’ in vivo has come from studies in which wild-type and gene-
targetedmice have been injected withmacrophages loadedwith
radiolabeled cholesterol, and then the appearance of label in
blood and feces is followed (deGoma et al., 2008). As a thera-
peutic strategy to promote lesion regression, investigators
have attempted to enhance macrophage cholesterol efflux by
increasing HDL or HDL-like particles or by increasing ABC trans-
porters (Tall et al., 2008; Rothblat and Phillips, 2010). Examples
include cholesteryl ester transfer protein inhibitors, LXR activa-
tors, and HDL mimetics (see section below on therapeutic
strategies). Though no drugs have yet been approved for this
purpose, this set of strategies continues to be a major focus in
cardiovascular drug discovery.
Macrophage Cholesterol Loading
A central question in atherogenesis is how the loading of
macrophages with lipoprotein-derived cholesterol alters mac-
rophage function, particularly with regard to specific proathero-
genic processes. Although markedly excessive loading of free
cholesterol in the face of defective cholesterol esterification
can have profound effects on macrophages in advanced
lesions (discussed below), the influence of cholesteryl ester
storage is less certain because it is stored in membrane-bound
neutral lipid droplets in the cytoplasm and is thus sequestered
from cellular membranes (Maxfield and Tabas, 2005). However,
even with normal esterification, macrophages exposed to344 Cell 145, April 29, 2011 ª2011 Elsevier Inc.atherogenic lipoproteins may have some degree of enrichment
of free cholesterol in the plasma membrane, which may
enhance inflammatory signaling through clustering-mediated
activation of signaling receptors due to the increased order
parameter of cholesterol-enriched membranes (Yvan-Charvet
et al., 2007; Zhu et al., 2008; Tang et al., 2009). In addition,
other proatherogenic lipids delivered to cells by lipoproteins,
particularly modified lipoproteins, may have potent effects.
As an example, oxysterols and oxidized phospholipids deliv-
ered through the uptake of oxidatively modified forms of
lipoproteins can induce macrophage apoptosis (Seimon
et al., 2010b).
As a new approach to the question of how lipoprotein loading
affects macrophage biology, a recent study used liquid chroma-
tography-electrospray ionization-tandem mass spectrometry
(LC-ESI-MS/MS) to identify proteins secreted by macrophages
using an in vivo model of unloaded versus cholesterol-loaded
macrophages (Becker et al., 2010). Gene ontology analysis of
proteins differentially expressed by peritoneal macrophages
obtained from chow- versus fat-fed Ldlr-deficient mice, which
have high levels of LDL and develop atherosclerosis when
placed on a high-fat diet, revealed networks involved in cytoskel-
etal regulation, vesicle-mediated transport, and lipid binding.
Interestingly, a subset of the appeared to be mediated by
a decrease in ApoE expression in the cholesterol-loaded macro-
phages. In terms of relevance to atherosclerosis, a very high
percentage of these proteins have been implicated in lesion
development in various gene-targeted mouse models, and
when Ldlr knockout mice were administered two drugs that
decrease atherosclerosis—a statin and a thiazolidinedione—
the differences in macrophage protein profiles were markedly
decreased. This study not only reveals potentially important
information about how macrophages respond to lipoprotein
loading in vivo, but also provides an example of how systems
biology approaches may be applied to this area of research.
Inflammatory Activation of Lesional Macrophages
The mechanisms and consequences of macrophage-mediated
inflammation comprise a central topic in atherosclerosis
research (Figure 3). Studies using immunohistochemistry and
RNA isolated from lesional macrophages by laser capturemicro-
dissection have clearly identified markers of inflammation in
macrophages in human and animal plaques (Shibata and Glass,
2009). Moreover, there have been hundreds of studies exam-
ining the effect of injected anti- or proinflammatory reagents or
of targeting pro- or anti-inflammatory genes in animal models
of atherosclerosis. In most cases, manipulations that decrease
inflammation have a protective effect on lesion area, and vice
versa. However, given the importance of inflammatory pathways
in endothelial cells (discussed above), the role of macrophage
inflammation per se can only be determined through studies
that specifically target this cell type.
Kanters et al. (2003) selectively ablated the Ikk2 gene, which is
involved in NF-kB activation in macrophages (and neutrophils)
with surprising results. The resultant mice were used as bone
marrow donors to Ldlr knockout mice, which were then fed
a high-fat ‘‘Western’’-type diet for 10 weeks. Although macro-
phages isolated from the chimeric mice had an 50% decrease
in NF-kB activation and lipopolysaccharide-induced TNFa
Figure 3. Signaling Pathways in Macro-
phages of Atherosclerotic Lesions
Various pro- and anti-inflammatory forces act on
the macrophage in atherosclerotic lesions,
leading to activation of downstream cascades,
such as the inflammasome, scavenger receptor
(SR)/Toll-like receptor (TLR) cooperative
signaling, endoplasmic reticulum (ER) stress,
expression of the sterol responsive network, and
efflux of cholesterol via ABCA1 and ABCG1
transporters. FC, free cholesterol.secretion, they showed a surprising increase in lesion area
compared with the control group. As an illustration of the impor-
tance of cell type specificity in the investigation of atherosclerosis,
a study in Apoe knockout mice showed that endothelial-targeted
inhibition of NF-kB signaling results in a decrease in lesion area,
which was associated with a decrease in recruitment of macro-
phages to lesions (Gareus et al., 2008). Although no definitive
mechanism linking increased lesion area to macrophage NF-kB
suppression was elucidated in the study by Kanters et al. (2003),
LPS-treatedmonocyte-derivedmacrophagescultured fromthese
mice showed decreased secretion of interleukin-10 (IL-10), which
is athero-protective in mice (Han et al., 2010).
In terms of pathways throughwhich NF-kBbecomes activated
in lesional macrophages, there are many studies showing that
global deletion of various members of the Toll-like receptor
(TLR) family or their adaptors decrease lesion area in fat-fed
Ldlr- or Apoe-deficient mice (Figure 3; Curtiss and Tobias,
2008). One of the few studies to address the role of TLR signaling
in macrophages in vivo showed that fat-fed Ldlr-deficient mice
transplanted with bone marrow from Tlr2 knockout mice had
decreased lesion area only when the mice were challenged
with a TLR2 activator (Mullick et al., 2005). In addition, a newly
described TLR heterodimer of TLR4/TLR6 has been shown to
cooperate with CD36 in activating NF-kB in response to oxidized
LDL (Stewart et al., 2010). Stimulation of the macrophage CD40
receptor by its ligand, CD40L, may also trigger NF-kB activation,
and fat-fed Ldlr knockout mice transplanted with bone marrow
from Cd40 knockout mice showed a reduction in lesion area
and inflammation (Lutgens et al., 2010).Cell 1A fascinating new area is the role of
macrophage inflammasome signaling in
atherosclerosis (Figure 3). When macro-
phages are exposed to crystalline mate-
rial, IL-1b and IL-18 protein maturation
and secretion are effected through an in-
flammasome complex involving multiple
proteins, notably NLRP3, ASC, and
caspase-1 (Duewell et al., 2010; Raja-
ma¨ki et al., 2010). This pathway can be
induced in cultured macrophages and in
mouse peritoneal macrophages in vivo
by cholesterol crystals, which have been
shown to exist even in early atheroscle-
rotic lesions. Cholesterol crystal-induced
macrophage inflammation involves phag-
olysosomal disruption, inflammasomecomponents, and the lysosomal proteases cathepsin B and
cathepsin L (Duewell et al., 2010; Rajama¨ki et al., 2010). Ldlr
knockout mice fed a Western diet and transplanted with marrow
cells lacking NLRP3 or ASC had a decrease in lesion size and in
levels of IL-18 (Duewell et al., 2010).
Macrophages in Advanced Atherosclerosis
As described in the previous sections, atherosclerosis is a nonre-
solving inflammatory condition, andmonocytes continue to enter
plaques and differentiate into macrophages as atherosclerotic
lesions progress. Importantly, macrophages contribute to size-
independent changes in plaque morphology, notably formation
of the necrotic core and thinning of the fibrous cap,which charac-
terize the ‘‘vulnerable’’ plaque (Figure 4). Analysis of these
processes in advanced plaque progression, e.g., through anal-
ysis of intravascular ultrasound data, may be particularly relevant
to acute atherothrombotic cardiovascular disease in humans
(Stoneet al., 2011). Lumenal thrombosis requires communication
between procoagulant and prothrombotic factors in the intima
with coagulation factors and platelets in the lumen. In 70% of
autopsy specimens that successfully identify the lesion respon-
sible for an acute vascular event (culprit lesion), this breach is
manifested as a rupture site (Virmani et al., 2002). The rupture
site, which is often located to the side (shoulder) of raised lesions,
is almost always in close proximity to areas of plaque necrosis
(necrotic core) and is associated with thinning of the protective
scar (fibrous cap) that normally covers inflamed atheromata.
One of the key questions in the atherosclerosis field is how
macrophages contribute to the features of such culprit lesions.45, April 29, 2011 ª2011 Elsevier Inc. 345
Figure 4. Macrophages in Advanced Atherosclerotic Lesions
(1) Macrophage foam cells undergo apoptosis as a result of prolonged
endoplasmic reticulum (ER) stress and other stimuli. (2) These apoptotic cells
are not effectively cleared by macrophages (defective efferocytosis) in
advanced lesions, (3) leading to secondary cellular necrosis. (4) Secondary
necrosis, over time, contributes to the formation of a necrotic core. (5) Smooth
muscle cell death and protease degradation of the extracellular matrix
weakens the fibrous cap, making it susceptible to rupture. (6) Exposure of the
thrombogenic material in the lesion causes platelet aggregation and thrombus
formation. Also note that living macrophages in advanced plaques can
contribute to vulnerable plaque formation through the secretion of cytokines,
proteases, and procoagulant/thrombotic factors.Fibrous Cap Thinning
Any process that decreases the synthesis of fibrous cap
collagen by intimal fibromyoblast-like smooth muscle cells
(SMCs) and/or contributes to cap collagen degradation would
be expected to promote the formation of plaques prone to
rupture (Figure 4). Vulnerable plaques show evidence of SMC
death and decreased numbers of SMCs, and in vitro data
show that macrophages can trigger apoptosis in SMCs by
activating their Fas apoptotic pathway and by secreting proa-
poptotic TNFa and nitric oxide (Boyle et al., 2003). Macrophages
may also decrease collagen synthesis in intimal SMCs
without actually killing the cells. For example, in regions of
vulnerable plaques that have defective clearance of apo-
ptotic cells (discussed below), macrophage secretion of TGFb
may be decreased (Fadok et al., 1998), which would
deprive neighboring SMCs of this important inducer of collagen
biosynthesis.
Macrophage-derived matrix metalloproteinases (MMPs) may
also be involved in thinning of the fibrous cap (Figure 4). MMPs
are a family of protease-activated enzymes that can degrade
various types of extracellular matrix (ECM) proteins. The regula-
tion of MMPs by athero-relevant factors is complex and is influ-
enced by transcriptional inducers and repressors and by
protease activators and inhibitors. Moreover, once activated,
certain MMPs can activate other ones.346 Cell 145, April 29, 2011 ª2011 Elsevier Inc.Studies showing a temporal and spatial correlation between
the presence of macrophages in rupture-prone shoulder regions
of plaques, thinning of the fibrous cap in these regions, and local
accumulation of activated MMPs, especially MMP-2 and
MMP-9, have stimulated great interest in the potential role of
MMPs in plaque rupture (Galis et al., 1994). Unfortunately,
because mouse models of atherosclerosis do not recapitulate
plaque rupture, specific molecular hypotheses in advanced
atherosclerosis have been difficult to test in vivo through gene-
targeting studies, leading investigations to focus on the
endpoints of atherosclerotic lesion area or collagen content or
aneurysm development instead. The lesion area studies have
yielded results that have beendifficult to synthesize into a unified,
mechanism-based hypothesis. However, when the endpoint of
advanced plaque collagen content has been studied in mouse
models lacking global or macrophage-derived MMP-13 and
-14, respectively, increases in plaque interstitial collagen were
observed (Deguchi et al., 2005; Schneider et al., 2008). In a study
that attempted to look directly at plaque disruption, macrophage
overexpression of wild-type MMP-9 had little effect in Apoe-
deficient mice due to a lack of MMP activation in plaques, but
overexpression of a constitutively active mutant form of MMP-
9 resulted in plaque fissuring (Gough et al., 2006).
In summary, observational data in vulnerable human plaques
and the known biology of MMPs have generated plausible
hypotheses regarding the role of certain MMPs in fibrous cap
thinning and plaque rupture. Moreover, there are other in vitro
and in vivo data implicating roles for macrophage-derived serine
proteases, such as neutrophil elastase, and cysteine proteases,
such as cathepsins S, K, and L, in the degradation of elastin and
collagen in advanced lesions (Liu et al., 2004). However, the few
molecular causation studies in mice addressing matrix protease
hypotheses have had to rely on the endpoints of plaque collagen
or elastin content, fibrous cap thinning, andmatrix fissuring. New
mouse models of true plaque rupture and ideally acute lumenal
thrombosis are needed to validate these ideas and to provide
the impetus for testing MMP inhibitor strategies in humans.
Plaque Necrosis
A second critical feature of dangerous plaques is the necrotic
core (Figure 4), which contributes to inflammation, thrombosis,
proteolytic plaque breakdown, and physical stress on the fibrous
cap (Virmani et al., 2002). Necrotic cores arise from the combina-
tion of apoptosis of advanced lesional macrophages and
defective phagocytic clearance (or efferocytosis) of the apoptotic
macrophages in advanced plaques (Tabas, 2010a). This combi-
nation is critical: macrophage death also occurs in early athero-
sclerotic lesions, but here, efferocytic clearance is efficient,
leading to decreases in lesion cellularity, inflammation, and pla-
que progression rather than an increase in plaque necrosis.
A number of processes in advanced lesions may trigger
macrophage death, and it is almost certain that a combination
of factors and processes plays a role in vivo. Examples include
growth factor deprivation, oxidative stress, and death receptor
activation by ligands that exist in advanced atheromata. A poten-
tial role for these and other processes is supported primarily by
studies with cultured macrophages, but, in most cases,
evidence of relevance in vivo through molecular-genetic causa-
tion studies is lacking. In this regard, several studies stand out in
terms of their effects on macrophage-induced plaque necrosis,
including the detrimental effect of NF-kB suppression (Kanters
et al., 2003) and the beneficial effects of interrupting type I inter-
feron signaling (Goossens et al., 2010) or TLR2/4 signaling (Sei-
mon et al., 2010b).
Another emerging concept that has gained in vivo support is
that prolonged activation of endoplasmic reticulum (ER) stress
pathways, primarily the unfolded protein response (UPR),
contributes to macrophage death and subsequent plaque
necrosis in advanced atheromata (Figure 3; Tabas, 2010b). The
UPR functions in normal physiology to correct disequilibria in
ER function, but when ER stress is abnormally prolonged, persis-
tent expression of the UPR effector C/EBP-homologous protein
(CHOP) can trigger apoptosis (Tabas and Ron, 2011). There are
many molecules and processes in advanced lesions that can
lead to UPR activation, and markers of ER stress are elevated
in these lesions. Importantly, CHOP expression and apoptosis
show a strong correlation with stage of human coronary artery
lesions, with both parameters markedly increased in plaques
with vulnerable morphology (Myoishi et al., 2007). Moreover,
the deletion of CHOP in mouse models of advanced
atherosclerosis suppresses lesional macrophage death and pla-
que necrosis (Thorp et al., 2009; Tsukano et al., 2010). Several
downstream mediators of CHOP have been implicated in this
process, including the Ca2+/calmodulin-dependent protein
kinase II (CaMKII), which is a central integrator of the apoptotic
execution pathway through activation of Fas, outer mitochon-
drial membrane permeabilization, STAT1, and NADPH oxidase
(NOX) (Timmins et al., 2009). In this context, a recent study impli-
cated oxidative stress and NOX in plaque necrosis in aged Ldlr-
deficient mice (Collins et al., 2009).
A potent inducer of prolonged ER stress in macrophages is
insulin resistance, and advanced plaques of type 2 diabetics
are characterized by very large necrotic cores independent of
lesion size (Tabas et al., 2010). Macrophages with defective
insulin signaling, such as occurs in type 2 diabetes, have an
amplified response to ER stress, leading to increased macro-
phage apoptosis and plaque necrosis in a mouse model of
atherosclerosis (Han et al., 2006). Another potential inducer of
ER stress in the settings of insulin resistance and obesity are
elevated saturated fatty acids (SFAs). These macrophage
apoptosis pathways induced by ER stress likely complement
other consequences of diabetes on advanced lesional macro-
phages, such as dyslipidemia-mediated proinflammatory
effects, to promote advanced plaque progression.
Two key concepts related to the mechanism and in vivo rele-
vance of ER stress-inducedmacrophage death are the presence
of compensatory cell survival pathways and the role of a ‘‘two-
hit’’ apoptotic process. In vitro and in vivo data indicate that there
is activation of a number of compensatory cell survival
pathways, including those involving NF-kB, Akt, p38a, and
autophagy (Tabas, 2010b). Importantly, the onset of apoptosis
correlates with eventual suppression of these pathways, and
apoptosis can be accelerated by experimentally interfering
with the pathways. The two-hit concept is based upon the likeli-
hood that ER stress in vivo may be more subtle than is often
modeled in vitro, where one can induce macrophage apoptosis
by high concentrations of ER stress-inducing agents. In thiscontext, subapoptotic, prolonged ER stress in macrophages
can set the stage for apoptosis induction by other subapoptotic
factors, leading to a synergistic apoptotic response. Remark-
ably, a potent and athero-relevant ‘‘second hit’’ in ER-stressed
macrophages is activation of innate immune pattern recognition
receptors (PRRs), which may have evolved as a host defense
response against invasive organisms that require living macro-
phages to survive (Seimon et al., 2010a). Two major classes of
PRRs, scavenger receptors (SRs) and TLRs, have been impli-
cated in atherosclerosis and are likely to be relevant to apoptosis
in ER-stressed macrophages. These PRR pathways trigger
apoptosis in ER-stressed macrophages by suppressing
compensatory cell survival pathways that are induced by pro-
longed ER stress and by adding to the burden of oxidative stress.
Importantly, atherosclerotic mousemodels lacking two SRs, SR-
A andCD36, or two TLRs, TLR4 and TLR2, are partially protected
against advanced lesional macrophage death and plaque
necrosis in a manner that cannot be explained simply by other
effects on early plaque progression. In addition, a lipoprotein in
humans called lipoprotein(a) [Lp(a)], which is highly associated
with atherothrombotic vascular disease and a carrier of oxidized
phospholipids (Bergmark et al., 2008), is a potent trigger of
apoptosis in ER-stressed macrophages through oxidized phos-
pholipid-mediated activation of CD36/TLR2, a second hit
pathway (Seimon et al., 2010b). Notably, a study in a transgenic
rabbitmodel showed that increasedplasmaLp(a) led to amarked
increase in plaque necrosis without altering signs of early lesion
development (Sun et al., 2002).
Defective Efferocytosis
Macrophage apoptosis by itself will not trigger plaque necrosis.
Rather, plaque necrosis results when apoptotic macrophages
are not sufficiently cleared by phagocytes (efferocytosis) (Tabas,
2010a). Efficient efferocytosis of apoptotic macrophages results
in at least three critical protective effects: (1) it clears the cells
before membrane damage leads to extracellular leakage of toxic
intracellular material; (2) it triggers an IL-10- and TGFb-mediated
anti-inflammatory response in the efferocytes; and (3) it
promotes survival of the efferocytes themselves so that they
do not succumb to potentially toxic factors in the ingested
apoptotic cells. This cell survival effect involves robust esterifica-
tion and efflux of cholesterol, efflux of proapoptotic oxidized
lipids, and activation of Akt and NF-kB cell survival pathways.
Efferocytosis is effected through phagocytic receptors (such
as the receptor tyrosine kinase MerTK and low-density lipopro-
tein receptor-related protein 1 [LRP-1]), apoptotic cell ligands
(such as phosphatidylserine and C1q), and bridging molecules
(such as Gas6) that enable recognition of apoptotic cells by the
phagocytes (Henson et al., 2001). In advanced atherosclerosis,
the combination of apoptotic macrophages and tissue necrosis
implies that efferocytosis is defective (Figure 4; Henson et al.,
2001). Direct support for this concept came from a study that
carefully quantified apoptotic cell-phagocyte association in
human advanced plaques and control tonsillar tissue (Schrijvers
et al., 2005). In tonsils, as expected, almost all of the apoptotic
cells were associated with phagocytes, whereas in advanced
atheromata, there were many free apoptotic cells. Similar results
have been found in mouse models of advanced atherosclerosis,
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targeting of effector molecules like MerTK, LRP-1, transglutami-
nase-2, C1q, and MFG-E8, there is increased presence of unin-
gested apoptotic cells, inflammation, and plaque necrosis
(Tabas, 2010a). Normal functioning of MerTK and LRP-1 may
be particularly important in preventing plaque necrosis because,
in addition to their roles in efferocytosis, MerTK suppresses
macrophage inflammation, and LRP-1 promotes macrophage
survival (Yancey et al., 2010).
The mechanisms of defective efferocytosis in advanced pla-
ques are not known. Overwhelming apoptosis is not likely to
be a major factor because efferocytosis is a high-capacity
process (Henson et al., 2001), and when apoptosis is increased
through genetic manipulations in early atherosclerotic lesions, in
which efferocytosis is not defective, apoptotic cells are
efficiently cleared (Tabas, 2010a). Rather, it is likely that efferocy-
tosis itself becomes defective in advanced lesions. Several
possible mechanisms might contribute to defective efferocyto-
sis, including oxidative stress-induced efferocyte death resulting
from defective cholesterol efflux after apoptotic cell engulfment
(Yvan-Charvet et al., 2010b); LP-associated hydrolysis of
oxidized phosphatidylserine on the surface of apoptotic cells
by phospholipase A2 (PLA2), which is a ligand for efferocytes
(Wilensky and Macphee, 2009); and protease-mediated
cleavage of the efferocytosis receptor MerTK (Sather et al.,
2007). Another mechanism that may be relevant to obesity is
based on in vitro and in vivo studies showing that macrophages
exposed to saturated fatty acids have defective engulfment of
apoptotic cells, perhaps due to changes in plasma membrane
structure (Li et al., 2009). These and other ideas will require care-
ful assessment in vulnerable plaques and then genetic causation
testing in mouse models of advanced atherosclerosis.
Dendritic Cells and Atherosclerosis
The distinction between macrophages and dendritic cells (DCs)
is a controversial topic, and it is further compounded by the likeli-
hood of plasticity between these two types of cells (Leo´n et al.,
2005). For the purpose of this section, DCs will be defined as
immune cells that internalize, process, and present antigen,
leading to activation or suppression of T cells. Both pre-athero-
sclerotic susceptible regions of arteries and established athero-
mata are populated with cells that have DC-like properties
(Paulson et al., 2010; Choi et al., 2009). The exact origins of
arterial wall and lesional DCs have not yet been definitively
delineated. A study in fat-fed Apoe knockout mice suggests
that a population of DCs in atherosclerotic lesions originates
from Ly-6Clo monocytes (Tacke et al., 2007). In terms of
functional significance, there is some evidence that lesional
DCs present antigen to and activate lesional T cells (Bobryshev,
2005). Moreover, early lesional DCs show two fundamental
characteristics that were previously ascribed to early lesional
macrophages: proliferation and foam cell formation (Paulson
et al., 2010). Attempts to probe these events through in vivo
causation studies have yielded mixed results. For example,
whereas acute ablation of DCs in Ldlr-deficient mice fed a high-
fat diet for 5 days resulted in a 55% decrease in foam cell lesion
area (Paulson et al., 2010), lesion area was only modestly
decreased in 10-week fat-fed Gmcsf and Ldlr double-knockout
mice, which is a model of chronic DC deficiency (Shaposhnik348 Cell 145, April 29, 2011 ª2011 Elsevier Inc.et al., 2007). Finally, in the setting of rapid and robust plasma
cholesterol unloading in a mouse model of atherosclerosis,
monocytic cells expressing CD11c, an often used DC marker,
emigrated from lesions in a CCR7-dependent manner, leading
to plaque regression (Feig et al., 2010). These intriguing studies
warrant further study of the role of DCs in atherosclerosis.
Methods of Investigation and Their Limitations
The reliability of the data cited in this Review is only as good as
the methods used to generate and analyze the data. Thus, it is
important to understand the limitations of both mechanistic
studies using cultured macrophages and in vivo studies using
animal models. There are many different types of cultured
macrophage models, with important differences between them
and actual lesional macrophages. In general, studies with
macrophages differentiated and activated in vivo, such as those
isolated from the peritoneum of mice treated under various
conditions, are probably the most relevant to atherosclerosis,
particularly in the setting of hypercholesterolemia, which
promotes loading with lipoprotein-derived lipid (Becker et al.,
2010). On the other hand, the use of immortal and highly prolifer-
ative macrophage cell lines, many of which are derived from
cancer cells, may yield results that have less relevance to
lesional macrophages. However, the only way to determine the
physiologic significance of findings with any cultured macro-
phage model is to test the findings in animal models of athero-
sclerosis and to show links with human studies.
In that context, there are several important points to consider
with regard to animal studies that attempt to explore macro-
phage-based hypotheses of atherosclerosis. In an attempt to
improve specificity for macrophages, many studies use bone
marrow transplantation of irradiated mice with donor cells
derived from bone marrow or fetal liver. However, such studies
may suffer from the effects of aortic irradiation and from the
fact that all bone marrow-derived cells are affected, including
neutrophils, T cells, B cells, and mast cells (Schiller et al.,
2001). Approaches to improve macrophage specificity in this
model include viral transduction of the donor cells with macro-
phage promoter-driven genes (Gough et al., 2006) and the use
of various cre-lox models for cell type-specific knockout, as in
Kanters et al. (2003). Although the latter approach has proven
to be very useful, it is occasionally hampered by heterogeneity
in cre-mediated recombination among individual lesional macro-
phages, and LysM promoter driving Cre expression also targets
neutrophils, which are becoming increasingly recognized as
participants in atherosclerosis (Baetta and Corsini, 2009).
In all cases, the greatest limitation is that animal models of
atherosclerosis may only partially reflect processes in human
atherosclerosis. As is apparent from the previous sections,
most atherosclerosis studies are carried out in mice, and the
two most widely used models are high-fat Western-type diet-
fed Ldlr knockout mice and chow-fed or Western diet-fed
Apoe knockout mice (Breslow, 1996). Ldlr-deficient mice are
a model of the rare human disease, homozygous familial
hypercholesterolemia, although LDL-induced atherosclerosis
is, in general, a very common process in humans.Apoe-deficient
mice have a form of remnant lipoproteinemia that is rare in
humans, but postprandial remnant lipoproteins likely contribute
to atherosclerosis in most humans. Influences of other systemic
risk factors in thesemice, such as levels of plasma HDL and diet-
induced insulin resistance, may or may not mimic certain
features of humans at risk for atherosclerotic vascular disease.
Moreover, most studies use mice on the atherosclerosis-
susceptible C57BL6/J background, which has a number of
features that likely affect macrophage biology and atheroscle-
rosis, including a proatherogenic increase in the Th1/Th2
balance (Schulte et al., 2008). Of note, the number of mice
used in many atherosclerosis studies is far lower than that
required by power calculations of appropriate sample size.
Moreover, studies in which pure backgrounds are not used
may be confounded by major differences in atherosclerosis
susceptibility among different strains of mice (Smith et al.,
2001), which is not always solved by using littermate controls
due to the influence of ‘‘passenger’’ genes clustered near the
targeted locus (Lusis et al., 2007). The use of pure C57BL6/J
ES cells for gene targeting studies, though not as efficient as
using other types of ES cells, may be the only way to avoid this
problem.
Finally, the choice of atherosclerosis endpoints may influence
the usefulness of the data obtained from animal studies. Most
studies use cross-sectional lesional area at the aortic root
and/or lipid staining of the lumenal surface of the whole aorta
(‘‘en face’’ analysis). These endpoints are relevant for early
atherogenesis and for processes related to early to midstage
lesion progression. Whereas the pathological features of early
to midstage lesions in mice share many common properties
with those in humans, lesion area is a poor predictor of clinical
disease in humans (Virmani et al., 2002). There has been
increasing interest in measuring certain advanced plaque
features in mouse models of atherosclerosis, including necrotic
core formation, thinning of the fibrous cap, breaches in the
subendothelial matrix, and measures of intimal cell apoptosis
and clearance of apoptotic cells by lesional phagocytes in
situ (efferocytosis). Although these features mimic those in
human advanced plaques, mouse atherosclerosis is not
a good model of true plaque rupture or acute lumenal throm-
bosis (Rosenfeld et al., 2002). There are claims that close
inspection of the innominate (brachiocephalic) artery in hyper-
cholesterolemic mice or the use of wire-induced injury in
various animal models can partially overcome this problem,
but true plaque rupture and acute lumenal thrombosis are rarely
seen, thus necessitating the development of new models of
these processes.
The litany of problems with methods of investigation in this
area of research may lead one to be skeptical about studies in
the atherosclerosis field. Indeed, the literature on cultured
macrophages and gene targeting studies in this area is over-
whelming, with many genes being reported to have ‘‘major’’
effects, all in the face of a significant number of studies showing
opposite results in different laboratories. Moreover, many
studies elucidate amechanism in vitro and show an overall effect
on lesion area in vivo but fail to link the two, that is, by demon-
strating that the mechanism gleaned from in vitro experiments
is operational and causative for the atherosclerosis changes
in vivo. However, technical and conceptual advances on many
fronts have recently increased the quality of work in this area,and consistent results are apparent in the most carefully con-
ducted and comprehensive investigations. In the end, the true
test of validity will be the demonstration that the results are
consistent with the results of human genetic studies and with
the outcomes of mechanism-based clinical trials.
Therapeutic Strategies
General Principles
The most effective and direct way to prevent or treat atheroscle-
rosis is to decrease subendothelial apoB-LP retention by
lowering apoB-LPs in the blood through lifestyle changes and
drugs (Steinberg et al., 2008). Studies have shown that apoB-
LP lowering both decreases monocyte entry (Potteaux et al.,
2011) and promotes macrophage egress from lesions (Feig
et al., 2010). Indeed, if circulating apoB-LPs could be lowered
below the threshold level required for subendothelial lipoprotein
retention prior to lesion initiation, which in Western society
occurs in the early teens, atherosclerosis could be completely
prevented. However, until this goal can be achieved safely and
universally, atherosclerotic disease will remain a major cause
of death, particularly in view of the increased global incidence
of important risk factors, such as obesity, physical inactivity,
insulin resistance, and, in emerging countries, smoking. Thus,
translational researchers in this area have considered the
concept that therapy directed at the arterial wall in general and
macrophages in particular could be additive or synergistic with
realistic goals of apoB-LP lowering.
Studies in mice have shown that prevention of monocyte entry
into lesions by antibody or gene-targeted neutralization of che-
mokines, chemokine receptors, or adhesion molecules lessens
atherosclerosis (Mestas and Ley, 2008). However, by the time
most subjects come under clinical care, many lesions are
already far advanced, so simply blocking monocyte entry at
this stage may not be able to reverse key aspects of plaque
progression, such as necrotic core formation. As mentioned
above, reduction of early lesional macrophages through forced
apoptosis and subsequent efferocytosis lessens lesion progres-
sion (Liu et al., 2005; Arai et al., 2005; Babaev et al., 2008);
however, attempts to increase macrophage apoptosis in coex-
isting advanced lesions that have defective efferocytosis may
cause the untoward effect of plaque necrosis and lead to lesion
vulnerability. Finally, the macrophage-related mechanisms
involved in atherosclerosis and host defense are not easily distin-
guishable, so many therapeutic approaches along these lines
will likely result in increased susceptibility to infectious organ-
isms. These problems could possibly be lessened by local
delivery systems, such as atherosclerosis-directed nanopar-
ticles (Chan et al., 2010), encapsulated macrophage-targeted
small interfering RNA (Aouadi et al., 2009), and stent-based
delivery systems (Nakano et al., 2007) or by identifying and
then targeting mechanisms that are more operational in athero-
sclerosis than in host defense.
Therapeutically inducing cholesterol efflux in macrophages or
macrophage precursors by raising HDL and/or cholesterol efflux
transporters is likely to have several beneficial, athero-specific
effects, including decreasing inflammation related to monocyto-
sis, suppressing activation of inflammatory signaling pathways in
macrophages, and increasing efferocytosis by preventingCell 145, April 29, 2011 ª2011 Elsevier Inc. 349
cholesterol- and oxysterol-induced efferocyte death (above) (Tall
et al., 2008). Moreover, HDL may have benefits beyond those
related to macrophage cholesterol efflux, including prevention
of subendothelial apoB-LP retention, decreasing activation of
endothelial cells, and reducing LDL oxidation. Animal studies in
which HDL-like particles are administered or in which HDL is
raised through genetic techniques show beneficial effects on
atherosclerosis. In humans, clinical trials are ongoing to assess
the effect of cholesteryl ester transfer protein (CETP) inhibitors,
which raise HDL and, importantly, also lower LDL. Although an
initial trial in this area showed disappointing results, possibly
due to off-target effects, the early results of a second CETP
inhibitor trial appear promising (Cannon et al., 2010). Similarly,
boosting macrophage ABC transporters through LXR agonists
is also beneficial in animal models, and LXR agonists are being
developed for trials in humans (Tall et al., 2008) (http://www.
bms.com/research/pipeline/Pages/default.aspx). LXR agonists
also have anti-inflammatory effects, and they increase the
expression of both CCR7, which promotes macrophage egress
from lesions, and MerTK, which mediates efferocytosis (Feig
et al., 2010; A-Gonzalez et al., 2009). PPAR agonists, like LXR
agonists, have potentially beneficial effects on cholesterol
metabolism and inflammation in macrophages in vitro and in
atherosclerosis in animal models (Rigamonti et al., 2008).
However, their actions are complex, multiple cell types are
affected, and currently available drugs have off-target effects,
some of which may actually exacerbate coronary artery disease.
Antioxidant therapy has been considered as a way to prevent
atherosclerosis, in part through effects on macrophage
processes (Witztum and Steinberg, 2001). The hope was that
antioxidants would prevent foam cell formation and subsequent
inflammatory changes by suppressing the formation of oxidized
lipoproteins and lipids and by decreasing oxidative stress
(Witztum and Steinberg, 2001). To the extent that scavenger
receptors mediate oxidized lipoprotein-induced foam cell forma-
tion, the aforementioned studies in mice lacking these receptors
(Moore et al., 2005; Manning-Tobin et al., 2009) have raised
uncertainties about this particular mechanism. Moreover, the
results of vitamin E trials in human heart disease have been
disappointing (Williams and Fisher, 2005). Nonetheless, this
overall strategy should not necessarily be abandoned because
oxidized lipoproteins and lipids exist in human atheromata; there
are sufficient in vitro mechanistic studies and preclinical studies
to support aspects of the oxidative stress hypothesis, including
roles in endothelial activation and advanced plaque progression;
and it is likely that vitamin E was a poor choice to test this
concept in humans. Thus, as we gain more knowledge about
specific oxidative processes that contribute to atherosclerosis,
such as possible roles for members of the NADPH oxidase
family, new therapeutic opportunities in this area may become
evident.
Targeting Macrophages in Advanced Lesions
Because only 2%–3% of atherosclerotic lesions cause acute
cardiovascular syndromes (Virmani et al., 2002), an efficient
strategy may be to therapeutically alter those macrophage
processes that are involved in advanced plaque progression.
As mentioned above, HDL/sterol efflux-based therapy and
well-conceived antioxidant approaches may be relevant to this350 Cell 145, April 29, 2011 ª2011 Elsevier Inc.topic. More direct attempts to block advanced plaque macro-
phage inflammation may be too nonspecific or subject to
adverse effects. For example, blocking TLRs would likely
suppress host defense mechanisms, and blocking NF-kB may
inhibit an important cell survival pathway in macrophages. A
targeted approach that has been considered is inhibition of
MMPs by preventing their secretion or activation or by blocking
their activity. However, as noted above, this is a complex area
with poor understanding of mechanism and lack of definitive
causation data in gene-targeting studies.Moreover, the interpre-
tations of preclinical MMP inhibitor drug studies are hindered by
the possibility of off-target effects, lack of specificity with regard
to members of the MMP family, and lack of documentation of
inhibition of MMP activity in plaques.
Our increasing understanding of how macrophages die in
advanced lesions has provided new targets that could be the
basis for drugs that prevent plaque necrosis, particularly inhibi-
tors of proapoptotic ER stress pathways (Tabas, 2010b).
However, a concern is that inhibition of macrophage apoptosis
would increase the number of living macrophages in advanced
plaques, which might cause damage even in the face of
decreased necrotic core formation. A more effective strategy
may be to enhance the phagocytic clearance of the deadmacro-
phages, which would result not only in decreased necrotic core
formation, but also in fewer macrophages in advanced lesions
(Tabas, 2010a). Strategies being explored include proinflamma-
tion resolution mediators such as lipoxins, resolvins, and
interleukin-10 receptor activators (Serhan et al., 2008); MerTK
inhibitors of cleavage (Sather et al., 2007); LXR activators, which
increase expression of MerTK, secretion of the efferocytosis
effector apolipoprotein E, and ABCA1/G1-mediated efflux of
toxic sterols (A-Gonzalez et al., 2009; Yancey et al., 2010;
Yvan-Charvet et al., 2010b); and PPARd activators, which
enhance efferocytosis in vitro (Mukundan et al., 2009). As with
early inflammatory processes, those involved in advanced
plaque progression may require local delivery systems.
Lessons from Human Genetic Studies
The above discussion has considered a relatively large number
of potential macrophage targets for therapeutic development
in the area of atherothrombosis. To what extent might the results
of human genetic studies on atherothrombotic coronary artery
disease guide the choice of which targets to pursue? There are
several caveats that need to be considered in this area: the
genes identified thus far each account for only a small
percentage of risk, as expected for a complex disorder; most
findings to date are associated with systemic risk factors, such
as high LDL or low HDL; and for many genome association
findings, the actual gene responsible for the effect is not known.
More specifically with regard to this Review, no genes associ-
ated with human coronary artery disease have been directly
tied to macrophage biology per se. However, several studies
have shown that polymorphisms associated with increased
levels of Lp(a), an inducer of cell death in ER-stressed macro-
phages, are associated with risk of coronary artery disease,
which is consistent with many clinical studies linking high levels
of Lp(a) with acute cardiovascular events (Tre´goue¨t et al., 2009).
Another risk locus is situated near the gene encoding CXCL12
(SDF-1), which is expressed in atherosclerotic lesional cells,
including macrophages (Abi-Younes et al., 2000). Although it is
unclear whether the CXCL12 gene is affected and, if so,
whether CXCL12 is protective or detrimental, recent work has
shown that risk of coronary artery disease is associated with
higher levels of plasma CXCL12 (Mehta et al., 2011). The locus
with the strongest and most consistent association with
coronary and peripheral atherosclerosis, but not necessarily
acute thrombotic vascular events, is located on chromosome
9p21.3 (Lotta, 2010). This locus is associated with aneurysms
in addition to coronary artery disease, potentially indicating
a mechanism related to arterial wall remodeling, but the mecha-
nism is not known. The locus contains an antisense noncoding
RNA in the INK4 locus (ANRIL) as well as the cell-cycle genes
CDKN2B, which encodes p15INK4B; CDKN2A, which encodes
p14ARF and p16INK4A; and MTAP. Several studies have begun
to study this genomic region in depth, but much more work is
needed to elucidate the mechanism of its association with
atherosclerosis and whether it might be associated with macro-
phage biology.
The Need for Improved Imaging Techniques
How would one test the effectiveness of an anti-atherosclerosis
drug targeted at lesional macrophages in humans? Unlike the
situation with LDL lowering therapy, there are no easily obtain-
able endpoints. The only sure sign of effectivenesswould be clin-
ical trials showing protection against acute atherothrombotic
vascular events, but such trials are extremely expensive, owing
to the large number of patients required and the relatively long
duration of the observation period. Thus, the drug industry has
taken a guarded approach toward the overall concept of arte-
rial-based strategies (Fryburg and Vassileva, 2011). The eventual
answermay lie in defining intermediate endpoints that are proven
to be reliable for predicting the ability of a drug to decrease acute
vascular events. Though circulating biomarkers would be ideal
for this purpose, their track record for this type of endeavor has
not yet been encouraging. However, given the unique
morphology of the plaques that actually cause acute coronary
syndromes, imaging modalities focused in this area may offer
the best hope. Indeed, this is a highly active area, and new
advances in fluorodeoxyglucose-based PET-CT (Positron emis-
sion tomography-computed tomography) to image activated le-
sional macrophages, together with novel high-resolution MRI
(magnetic resonance imaging) techniques to assess plaque
necrosis, are examples of advances in this area (Sadeghi et al.,
2010). Functional imaging based, for example, on detecting
MMP activation in lesions is another area in development at the
preclinical level (Deguchi et al., 2006). In all likelihood, success
will depend on a combination of approaches. Moreover, there
will be a significant lag period before such methods can be used
routinely to evaluate new drugs because the first step will be to
demonstrate that they can accurately predict acute vascular
events, followed by repeated demonstrations that changes in
these imaging endpoints with athero-protective drugs are
directly associated with improvement in clinical outcome.
Conclusions and Perspectives
There are many thousands of papers in the literature on the cell-
based mechanisms and in vivo processes operative in athero-
sclerosis, which is appropriate for the leading cause of death inthe industrialized world. The emphasis in this Review has been
to highlight major concepts of how macrophages affect plaque
initiation and progression. In this regard, it is instructive to
compare this current state of knowledge with that reported in
a classic and highly cited Review article by Russell Ross in
1986 (Ross, 1986). As expected, progress during the last
25 years has been built upon earlier findings, as illustrated by
the appreciation in 1986 that monocyte-endothelial interactions
give rise to macrophage-derived foam cells in lesions, which
‘‘may represent a form of inflammatory response.’’ However,
most emphasis was placed on endothelial ‘‘injury’’ and growth
factor-induced smooth muscle cell proliferation rather than the
critical role of subendothelial apoB-LP retention in triggering
lesion initiation and the nature of the maladaptive inflammatory
response that promotes plaque necrosis. The last 25 years
have witnessed major advances in understanding the molec-
ular-cellular mechanisms and in vivo relevance of processes
involved in plaque development and advanced plaque progres-
sion, such as macrophage inflammatory and apoptotic signaling
pathways, as well as in monocyte biology and macrophage
cholesterol efflux.
There are several principles reviewed herein that are worth
reiterating. First, athersclerosis, including the roles of macro-
phages in the disease process, would not be the critical topic
it is today if we had safe and effective ways of markedly lowering
apoB-LPs in every human before they reach their teen years,
the time at which lesion initiation begins. Unfortunately, we are
far from this goal. Second, most if not all of the processes by
which macrophages promote atherothrombotic vascular
disease have evolved to optimize our chances of survival to
reproductive age. Thus, for example, the inflammatory and
oxidative processes through which macrophages promote
atherosclerosis are used by these cells to kill infectious organ-
isms (Seimon et al., 2010a), and ER stress-signaling pathways
active in advanced plaque progression are essential for macro-
phage cytokine production during host defense (Martinon
et al., 2010). Third, despite the intense effort to determine how
macrophages affect atherosclerosis, there is a remarkable
number of fundamental issues that remain mysterious. For
example, we are far from understanding how the most obvious
and distinguishing feature of lesional macrophages, lipid
loading, precisely affects macrophage biology and atheroscle-
rotic processes. Solving these mysteries will require a combina-
tion of innovative ideas and new and improvedmethods of inves-
tigation. Finally, investigators in the field must continually
evaluate how work in this area can be translated into new and
useful therapeutic strategies. Even as we continue to attack
the unsolved mysteries in this area, there are already an abun-
dance of plausible targets. However, there are two rate-limiting
steps: specificity issues, particularly with regard to the possibility
of compromising host defense, and the feasibility of evaluating
the effectiveness of arterial wall-based therapy in humans
without the requirement for long and costly clinical trials that
rely on delayed disease endpoints. The former area is likely to
benefit from innovative drug delivery systems, such as arterial
wall-targeted nanoparticles, and the latter from new imaging
procedures focused on the features of the vulnerable plaque.
As is the case with the identification of the targets themselves,Cell 145, April 29, 2011 ª2011 Elsevier Inc. 351
both of these challenges in drug development will benefit from
continued mechanistic and in vivo studies on the cellular biology
of macrophages in atherosclerosis.
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